Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer

NCT05721248 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT05721248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05721248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 19, 2023
Completion date
June 30, 2036
Enrollment
82 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer, metastatic breast cancer